High-Dependency Unit, Department of Clinical and Experimental Medicine, Azienda Ospedaliero-Universitaria Careggi, Lg. Brambilla 3, 50134, Florence, Italy.
Department of Clinical and Experimental Medicine, University of Florence, Florence, Italy.
Intern Emerg Med. 2019 Apr;14(3):459-466. doi: 10.1007/s11739-018-1990-z. Epub 2018 Dec 7.
To evaluate if the assessment of coagulation abnormalities at ED admission could improve prognostic assessment of septic patients. This report utilizes a portion of the data collected in a prospective study, with the aim to identify reliable biomarkers for an early sepsis diagnosis. In the period November 2011-December 2016, we enrolled 268 patients, admitted to our High-Dependency Unit with a diagnosis severe sepsis/septic shock. Study-related blood samplings were performed at ED-HDU admission (T0), after 6 h (T6) and 24 h (T24): D-dimer, thrombin-antithrombin complex (TAT) and prothrombin fragment F1 + 2 levels were analyzed. The primary end-points were day-7 and in-hospital mortality. Day-7 mortality rate was 16%. D-dimer (T0: 4661 ± 4562 µg/ml vs 3190 ± 7188 µg/ml; T6: 4498 ± 4931 µg/ml vs 2822 ± 5623 µg/ml; T24 2905 ± 2823 µg/ml vs 2465 ± 4988 µg/ml, all p < 0.05) and TAT levels (T0 29 ± 45 vs 22 ± 83; T6 21 ± 22 vs 15 ± 35; T24 16 ± 19 vs 13 ± 30, all p < 0.05) were higher among non-survivors compared to survivors. We defined an abnormal coagulation activation (COAG+) as D-dimer > 500 µg/ml and TAT > 8 ng/ml (for both, twice the upper normal value). Compared to COAG-, COAG+ patients showed higher lactate levels at the earliest evaluations (T0: 3.3 ± 2.7 vs 2.5 ± 2.3, p = 0.041; T6: 2.8 ± 3.4 vs 1.8 ± 1.6, p = 0.015); SOFA score was higher after 24 h (T24: 6.7 ± 3.1 vs 5.4 ± 2.9, p = 0.008). At T0, COAG+ patients showed a higher day-7 mortality rate (HR 2.64; 95% CI 1.14-6.11, p = 0.023), after adjustment for SOFA score and lactate level. Presence of abnormal coagulation at ED admission shows an independent association with an increased short-term mortality rate.
为了评估在急诊入院时评估凝血异常是否可以改善脓毒症患者的预后评估。本报告利用了一项前瞻性研究中收集的数据的一部分,旨在确定早期脓毒症诊断的可靠生物标志物。在 2011 年 11 月至 2016 年 12 月期间,我们招募了 268 名因严重脓毒症/脓毒性休克而入住我们的高依赖病房的患者。在急诊-高依赖病房入院时(T0)、6 小时(T6)和 24 小时(T24)进行了与研究相关的血液采样:分析了 D-二聚体、凝血酶-抗凝血酶复合物(TAT)和凝血酶原片段 F1+2 水平。主要终点是第 7 天和住院死亡率。第 7 天死亡率为 16%。D-二聚体(T0:4661±4562µg/ml 比 3190±7188µg/ml;T6:4498±4931µg/ml 比 2822±5623µg/ml;T24:2905±2823µg/ml 比 2465±4988µg/ml,均为 p<0.05)和 TAT 水平(T0:29±45 比 22±83;T6:21±22 比 15±35;T24:16±19 比 13±30,均为 p<0.05)在幸存者中较高。我们将异常凝血激活(COAG+)定义为 D-二聚体>500µg/ml 和 TAT>8ng/ml(两者均为正常值的两倍)。与 COAG-相比,COAG+患者在最早的评估中显示出更高的乳酸水平(T0:3.3±2.7 比 2.5±2.3,p=0.041;T6:2.8±3.4 比 1.8±1.6,p=0.015);24 小时后 SOFA 评分更高(T24:6.7±3.1 比 5.4±2.9,p=0.008)。在 T0 时,COAG+患者第 7 天的死亡率更高(HR 2.64;95%CI 1.14-6.11,p=0.023),调整 SOFA 评分和乳酸水平后。急诊入院时异常凝血的存在与短期死亡率的增加有独立关联。